Tivic Health Systems Inc(TIVC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -9.33 | Insider Own | 2.41% | Shs Outstand | 2.9M | Perf Week | 23.89% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | 71.78% | Shs Float | 2.8M | Perf Month | 41.59% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 8.01% | Short Float | 2.28% | Perf Quarter | 17.15% |
| Income | -0.01B | P/S | 8.4 | EPS this Y | - | Inst Trans | 2.89% | Short Ratio | 0.26 | Perf Half Y | -50.53% |
| Sales | 0.00B | P/B | 0.42 | EPS next 5Y | - | ROA | -156% | Short Interest | 0.06M | Perf YTD | -3.45% |
| Book/sh | 3.36 | P/C | 1.17 | EPS past 3/5Y | 83.77% 59.16% | ROE | -178.18% | 52W High | -81.46% ($7.55) | Perf Year | -80.34% |
| Cash/sh | 1.2 | P/FCF | - | Sales past 3/5Y | - | ROIC | -134.25% | 52W Low | 93.99% ($0.72) | Perf 3Y | -99.41% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 82.22% | Gross Margin | -58.51% | Volatility(W/M) | 8.1% 11% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 1.21 | Sales Y/Y TTM | -49.63% | Oper. Margin | -1548.96% | ATR (14) | 0.12 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.86 | EPS Q/Q | 49.98% | Profit Margin | -1557.26% | RSI (14) | 68.68 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.86 | Sales Q/Q | 15.87% | SMA20 | 32.11% ($1.06) | Beta | 2.18 | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | 2025/11/14 | SMA50 | 46.97% ($0.95) | Rel Volume | 1.32 | Prev Close | $1.33 |
| Employees | 52 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -33.34% ($2.1) | Avg Volume(3M) | 0.25M | Price | $1.4 |
| IPO | 2021/11/11 | Option/Short | No/Yes | Trades | 1432 | Volume | 327,188 | Change | 5.26% |
A clinical-stage healthcare company that originated as a non-invasive medical device firm before pivoting its business model to develop biopharmaceuticals for oncology and radiation countermeasure applications. Its core asset is entolimod, a candidate therapy for treating Acute Radiation Syndrome (ARS), and it is a micro-cap stock that views government contracts (such as those with BARDA) and government stockpiling demand as its primary market opportunities.
Over the past 1 year, on the lower side
81% below its 1-year high.
Traded more than usual. That is 132% of its average volume.
TIVC has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $840. Peers typically go for $130.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -99.4%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 8.0%.
Tap to view numbers
It ranks #127 of 141 in the industry
Based on market cap of $4M.
TNON#125 Tenon Medical Inc $4M PER - 
WOK#126 Work Medical Technology Group Ltd $4M PER - TIVC#127 Tivic Health Systems Inc $4M PER - 
XAIR#127 Beyond Air Inc $4M PER - 
TRIB#128 Trinity Biotech Plc ADR $4M PER - 
FAQ
What kind of company is TIVC?
TIVC belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of TIVC?
The market cap of TIVC is approximately $4M, ranking 5,706 within its sector.
What is the 52-week high and low for TIVC?
TIVC has recorded a 52-week high of $7.55 and a low of $0.72.
